Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.36 |
| ▸ | CDK2 | P24941 | 6/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | PDE8A | O60658 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26734621 | 0.79 | SMN1; SMN2 (0.37) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL30614458 | 0.75 | SPR (0.42) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL10830639 | 0.72 | KMT2A (0.33) | KMT2ALMNAKDM4E | |
| SCHEMBL2573194 | 0.71 | CCNB2 (0.44) | KMT2AMEN1LMNAKDM4EGAA | |
| SCHEMBL557383 | 0.67 | MAP2K1 (0.44) | CCNE1CDK2CCNE2PDE3BPDE3A | |
| SCHEMBL22490641 | 0.65 | EGLN2 (0.35) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL2571757 | 0.64 | PDE10A (0.33) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL22490649 | 0.64 | EGLN2 (0.34) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL2450155 | 0.64 | PDE3B (0.37) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL24438415 | 0.63 | CHEK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079983-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079984-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079985-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| EP-1912643-A2 | 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING INFECTIONS WITH FLAVIVIRIDAE | Idenix (Cayman) Limited (KY) | 2008-04-23 | — | — | EP | disclosed |
| US-20060040944-A1 | 5-Aza-7-deazapurine derivatives for treating Flaviviridae | IDENIX PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006000922-A2 | 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING INFECTIONS WITH FLAVIVIRIDAE | IDENIX (CAYMAN) LIMITED (KY) | 2006-01-05 | — | — | WO | disclosed |
| EP-0004173-B1 | 2,3-DIHYDROIMIDAZO (1,2-C) PYRIMIDINES, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | ELI LILLY AND COMPANY (US) | 1982-09-22 | — | — | EP | disclosed |
| EP-0004173-A1 | 2,3-Dihydroimidazo (1,2-c) pyrimidines, their preparation, formulations containing them and their use as pharmaceuticals | ELI LILLY AND COMPANY (US) | 1979-09-19 | — | — | EP | disclosed |
| US-4153695-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040944-A1 | 5-Aza-7-deazapurine derivatives for treating Flaviviridae | TPMT, NUDT15, DUSP5 | GRIN2D 4279/4885GRIN3B 3128/4885GRIA1 2589/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | GRIN2D 3476/4885GRIN3B 3838/4885GRIA1 862/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GRIN2D 3476/4885GRIN3B 3838/4885GRIA1 862/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | GRIN2D 4689/4885GRIN3B 4554/4885GRIA1 3452/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GRIN2D 3476/4885GRIN3B 3838/4885GRIA1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.